{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:37:31Z","timestamp":1786700251844,"version":"build-2736575974"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction increasingly shapes the burden of hepatocellular carcinoma (HCC) by linking obesity, type 2 diabetes, insulin resistance, and metabolic dysfunction-associated steatotic liver disease (MASLD) to steatohepatitis, fibrosis, cirrhosis, and HCC. GLP-1 receptor agonists (GLP-1RAs) target several upstream metabolic drivers, but the structure and evolution of research connecting GLP-1RAs with the MASLD\u2013MASH\u2013HCC continuum remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Web of Science Core Collection, PubMed, and Scopus for English-language articles and reviews published from January 1, 2000, to May 25, 2026. A GLP-1RA or related incretin concept was mandatory for inclusion, together with relevance to HCC and metabolic liver disease. After removal of 450 duplicates and relevance screening, 534 publications were analyzed for publication trends, collaboration networks, journals, authors, and keyword evolution. Bibliometric themes were subsequently interpreted through an expert synthesis of independent mechanistic and clinical evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Research output accelerated after 2020; the United States remained the leading contributor, while China showed rapid recent growth. Keyword evolution shifted from glucose lowering, obesity, and insulin resistance toward MASLD\/MASH, liver fibrosis, HCC risk, drug therapy, and clinical outcomes. These bibliometric patterns informed\u2014but did not independently establish\u2014a four-domain interpretive framework comprising systemic metabolic remodeling, intrahepatic lipotoxicity relief, inflammation\u2013fibrosis regulation, and HCC risk and premalignant microenvironment modulation, with clinical translation considered across all four domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Research linking GLP-1RAs to the MASLD\u2013MASH\u2013HCC continuum is expanding rapidly. The available evidence suggests that GLP-1RAs are best investigated as upstream disease-modifying and risk-reducing agents in metabolically high-risk populations rather than as established direct anti-HCC therapies. Prospective studies with stage-specific liver and cancer outcomes are required to test this translational hypothesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1913929","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:10:22Z","timestamp":1786698622000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping GLP-1 receptor agonist research across the MASLD\u2013MASH\u2013HCC continuum: a bibliometric and translational analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yannan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Hepatobiliary Surgery, People\u2019s Hospital of Ningxia Hui Autonomous Region","place":["Yinchuan, China"]},{"name":"Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xusheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bendong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hepatobiliary Surgery, People\u2019s Hospital of Ningxia Hui Autonomous Region","place":["Yinchuan, China"]},{"name":"Ningxia Medical University","place":["Yinchuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","article-title":"Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2021","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/dmrr.1291","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Wang","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3350\/cmh.2020.0176","article-title":"Obesity and the risk of primary liver cancer: a systematic review and meta-analysis","volume":"27","author":"Sohn","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e100196","DOI":"10.1136\/egastro-2025-100196","article-title":"Key takeaways from the updated multidisciplinary European MASLD guidelines","volume":"3","author":"Horn","year":"2025","journal-title":"eGastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e100430","DOI":"10.1136\/egastro-2026-100430","article-title":"From static labels to dynamic trajectories: MASLD\u2013MetALD\u2013ALD as a dynamic continuum within the framework of steatotic liver disease","volume":"4","author":"Chen","year":"2026","journal-title":"eGastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/dom.70545","article-title":"Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease\/metabolic dysfunction-associated steatohepatitis: key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions","author":"Chen","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of NAFLD","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e100218","DOI":"10.1136\/egastro-2025-100218","article-title":"Steatotic liver disease and cancer: from pathogenesis to therapeutic targets","volume":"3","author":"Yang","year":"2025","journal-title":"eGastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1053\/j.gastro.2024.04.029","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","volume":"167","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.joi.2017.08.007","article-title":"Bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetr"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","article-title":"Software survey: VOSviewer, a computer program for bibliometric mapping","volume":"84","author":"van Eck","year":"2010","journal-title":"Scientometrics"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1097\/HEP.0000000000000712","article-title":"Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: a Scandinavian cohort study","volume":"79","author":"Engstrom","year":"2024","journal-title":"Hepatology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1038\/onc.2017.38","article-title":"The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through the cAMP-PKA-EGFR-STAT3 axis","volume":"36","author":"Zhou","year":"2017","journal-title":"Oncogene"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.3390\/ijms21165722","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","volume":"21","author":"Kojima","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12902-024-01775-2","article-title":"Risk of hepatocellular carcinoma with glucagon-like peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis","volume":"24","author":"Shabil","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"107401","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol Res"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bph.12313","article-title":"Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation","volume":"171","author":"Pabreja","year":"2014","journal-title":"Br J Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic beta-cells: mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.molmet.2019.07.008","article-title":"Direct and indirect effects of liraglutide on hypothalamic POMC and NPY\/AgRP neurons: implications for energy balance and glucose control","volume":"28","author":"He","year":"2019","journal-title":"Mol Metab"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e2037","DOI":"10.1038\/cddis.2015.381","article-title":"Obesity and cancer, a case for insulin signaling","volume":"6","author":"Poloz","year":"2015","journal-title":"Cell Death Dis"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jhep.2013.11.031","article-title":"Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends","volume":"60","author":"Matter","year":"2014","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J Clin Invest"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.2147\/DDDT.S69004","article-title":"Leptin signaling molecular actions and drug target in hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nrgastro.2016.85","article-title":"The role of the gut microbiota in NAFLD","volume":"13","author":"Leung","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"150","author":"Machado","year":"2016","journal-title":"Gastroenterology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e100115","DOI":"10.1136\/egastro-2024-100115","article-title":"Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis","volume":"2","author":"Wade","year":"2024","journal-title":"eGastroenterology."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e100159","DOI":"10.1136\/egastro-2024-100159","article-title":"Protein tyrosine phosphatase delta is a STAT3-phosphatase and suppressor of metabolic liver disease","volume":"3","author":"Roca Suarez","year":"2025","journal-title":"eGastroenterology."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH","volume":"66","author":"Mridha","year":"2017","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"e002343","DOI":"10.1136\/bmjgast-2026-002343","article-title":"Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics","volume":"13","author":"Li","year":"2026","journal-title":"BMJ Open Gastroenterol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"e001895","DOI":"10.1136\/bmjgast-2025-001895","article-title":"Liver fibrosis with persistently normal alanine transaminase levels exhibits a distinct treatment response in MASLD","volume":"12","author":"Luo","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.3748\/wjg.v22.i8.2512","article-title":"Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice","volume":"22","author":"Yamamoto","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e100465","DOI":"10.1136\/egastro-2026-100465","article-title":"Immunotherapy in HCC: aetiology matters","volume":"4","author":"Ng","year":"2026","journal-title":"eGastroenterology"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamaoncol.2025.2681","article-title":"GLP-1 receptor agonists and cancer risk in adults with obesity","volume":"11","author":"Dai","year":"2025","journal-title":"JAMA Oncol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"e001832","DOI":"10.1136\/bmjgast-2025-001832","article-title":"Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions","volume":"12","author":"Wongsuwan","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e001404","DOI":"10.1136\/bmjgast-2024-001404","article-title":"Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD","volume":"11","author":"Schreiner","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"e001670","DOI":"10.1136\/bmjgast-2024-001670","article-title":"eHealth interventions and patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis","volume":"12","author":"Zafar","year":"2025","journal-title":"BMJ Open Gastroenterol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913929\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:10:24Z","timestamp":1786698624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1913929\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":68,"alternative-id":["10.3389\/fmed.2026.1913929"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1913929","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1913929"}}